Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

stephar (u.k.) ltd - nifedipine - modified-release tablet - 20mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - estradiol valerate - oral tablet - 2mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

necessity supplies ltd - nifedipine - modified-release tablet - 20mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - hydrocortisone acetate; clotrimazole - cutaneous cream - 10mg/1gram ; 10mg/1gram

Združene države Amerike - angleščina - NLM (National Library of Medicine)

baxalta us inc. - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibrinogen human 90 mg in 1 ml - artiss is indicated to adhere autologous skin grafts to surgically prepared wound beds resulting from burns in adult and pediatric populations greater than or equal to 1 year of age. artiss is indicated to adhere tissue flaps during facial rhytidectomy surgery (face-lift). artiss is not indicated as an adjunct to hemostasis. do not inject artiss directly into blood vessels. intravascular application of artiss may result in life-threatening thromboembolic events. do not use artiss in individuals with a known hypersensitivity to aprotinin and/or hypersensitivity to any of the active substances or excipients (see warnings/precautions, hypersensitivity/allergic/anaphylactic reactions (5.1) and adverse reactions (6)). pregnancy category c animal reproduction studies have not been conducted with artiss. it is also not known whether artiss can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. some viruses, such as parvovirus b19, are particularly difficult to remove or inact

Združene države Amerike - angleščina - NLM (National Library of Medicine)

baxalta us inc. - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibrinogen human 90 mg in 1 ml - artiss is indicated to adhere autologous skin grafts to surgically prepared wound beds resulting from burns in adult and pediatric populations greater than or equal to 1 year of age. artiss is not indicated for hemostasis. do not inject artiss directly into blood vessels. intravascular application of artiss may result in life-threatening thromboembolic events. do not use artiss in individuals with a known hypersensitivity to aprotinin and/or hypersensitivity to any of the active substances or excipients (see warnings/precautions, hypersensitivity/allergic/anaphylactic reactions (5.1) and adverse reactions, overall adverse reactions (6.1)). pregnancy category c animal reproduction studies have not been conducted with artiss. it is also not known whether artiss can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. some viruses, such as parvovirus b19, are particularly difficult to remove or inactivate at this time. parvovirus b19 most seriously affects pregnant women (f

Združene države Amerike - angleščina - NLM (National Library of Medicine)

baxalta us inc. - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibrinogen human 90 mg in 1 ml - tisseel is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. tisseel is effective in heparinized patients. tisseel is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies. do not inject tisseel directly into the circulatory system or into highly vascularized tissue. intravascular application of tisseel can lead to intravascular coagulation, can result in life-threatening thromboembolic events, and can increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients (see warnings and precautions(5.3) and adverse reactions (6.2)).   do not use tisseel in individuals with a known hypersensitivity to aprotinin  (see warnings and pre

Združene države Amerike - angleščina - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride 5 mg - levitra is indicated for the treatment of erectile dysfunction. nitrates: administration of levitra with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated (see clinical pharmacology , pharmacodynamics , effects on blood pressure and heart rate when levitra is combined with nitrates ). consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors may potentiate the hypotensive effects of nitrates. a suitable time interval following levitra dosing for the safe administration of nitrates or nitric oxide donors has not been determined. hypersensitivity: levitra is contraindicated for patients with a known hypersensitivity to any component of the tablet.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

baxalta us inc. - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibrinogen 90 mg in 1 ml - tisseel is a fibrin sealant indicated for use as an adjunct to hemostasis in surgeries involving cardiopulmonary bypass and treatment of blunt or penetrating splenic injuries when control of bleeding by conventional surgical techniques, including suture, ligature, and cautery, is ineffective or impractical. tisseel is a hemostatic agent that may be used in fully heparinized patients undergoing cardiopulmonary bypass. tisseel is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies. do not inject tisseel directly into the circulatory system or into highly vascularized tissue. intravascular application of tisseel can lead to intravascular coagulation, may result in life-threatening thromboembolic events, and may increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients (see warnings and precautions, use in cardiopulmonary surgery (5.3

Združene države Amerike - angleščina - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - levitra is indicated for the treatment of erectile dysfunction. nitrates: administration of levitra with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated (see clinical pharmacology , pharmacodynamics , effects on blood pressure and heart rate when levitra is combined with nitrates ). consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors may potentiate the hypotensive effects of nitrates. a suitable time interval following levitra dosing for the safe administration of nitrates or nitric oxide donors has not been determined. hypersensitivity: levitra is contraindicated for patients with a known hypersensitivity to any component of the tablet.